25 related articles for article (PubMed ID: 29894077)
1. Immunohistochemical p16 overexpression and Rb loss correlate with high-risk human papillomavirus infection in endocervical adenocarcinomas.
Yasutake N; Yamamoto H; Kuga R; Jiromaru R; Hongo T; Katayama Y; Sonoda K; Yahata H; Kato K; Oda Y
Histopathology; 2024 Jun; 84(7):1178-1191. PubMed ID: 38445509
[TBL] [Abstract][Full Text] [Related]
2. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.
Stolnicu S; Barsan I; Hoang L; Patel P; Terinte C; Pesci A; Aviel-Ronen S; Kiyokawa T; Alvarado-Cabrero I; Pike MC; Oliva E; Park KJ; Soslow RA
Am J Surg Pathol; 2018 Feb; 42(2):214-226. PubMed ID: 29135516
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma.
Khoury T; Tan D; Wang J; Intengan M; Yang J; Alrawi S; Yan P; Byrd JC
BMC Clin Pathol; 2006 Jan; 6():1. PubMed ID: 16409624
[TBL] [Abstract][Full Text] [Related]
4. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
[TBL] [Abstract][Full Text] [Related]
5. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
Kong CS; Beck AH; Longacre TA
Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
[TBL] [Abstract][Full Text] [Related]
6. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.
Esheba GE
J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407
[TBL] [Abstract][Full Text] [Related]
7. Differential Diagnosis between Primary Endocervical and Endometrial Adenocarcinoma using Immunohistochemical Staining of Estrogen Receptor, Vimentin, Carcinoembryonic Antigen and p16.
Yanaranop M; Ayuwat S; Nakrangsee S
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S106-15. PubMed ID: 27266224
[TBL] [Abstract][Full Text] [Related]
8. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
[TBL] [Abstract][Full Text] [Related]
9. Detection of high-risk human papillomavirus DNA and immunohistochemical expressions of p16, vimentin, ER, and PR in primary endocervical and endometrial adenocarcinomas.
Xiong Y; Xiong YY; Xu ZG
Eur J Gynaecol Oncol; 2016 Aug; 37(4):517-521. PubMed ID: 29894077
[TBL] [Abstract][Full Text] [Related]
10. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
11. Tissue-based Immunohistochemical Biomarker Accuracy in the Diagnosis of Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review of the Literature and Meta-Analysis.
Lee S; Rose MS; Sahasrabuddhe VV; Zhao R; Duggan MA
Int J Gynecol Pathol; 2017 Jul; 36(4):310-322. PubMed ID: 27801764
[TBL] [Abstract][Full Text] [Related]
12. Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors.
Pirog EC
Arch Pathol Lab Med; 2017 Dec; 141(12):1653-1667. PubMed ID: 28644686
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
